论文部分内容阅读
目的 观察国产紫杉醇(紫素)及吉西他滨(泽菲)分别与顺铂组成联合方案,治疗复发或有远处转移乳腺癌的疗效、不良反应。方法 Ⅲ~ Ⅳ期乳腺癌患者80例,分为紫素组(紫素+顺铂)41 例、泽菲组(泽菲+顺铂)39 例。结果 紫素组有效率63.4%(26/41),中位缓解期8个月(7.5~19个月);泽菲组有效率 53.8%(21/39),中位缓解期 6 个月(4~15.5 个月)。组间疗效、缓解时间无显著性差异(P>0.05)。主要不良反应为骨髓抑制、消化道反应,均为可逆性。结论 紫素、泽菲分别与顺铂组成二药联合方案对复发或有远处转移、特别是蒽环类耐药的晚期乳腺癌的近期疗效和不良反应相当。
Objective To observe the efficacy and side effects of domestic paclitaxel (Ziyu) and gemcitabine (Zefei) combined with cisplatin in the treatment of relapsed or distant metastatic breast cancer. Methods Ⅲ ~ Ⅳ breast cancer patients 80 cases, divided into purple group (purple + cisplatin) in 41 cases, Zefei group (zafi + cisplatin) in 39 cases. Results The effective rate was 63.4% (26/41) in the purpura group and 8 months (7.5-19 months) in the metalaxyl group, 53.8% (21/39) in the metalaxyl group, and 6 months in the metalaxyl group 4 ~ 15.5 months). There was no significant difference between the two groups in curative effect and relieving time (P> 0.05). The main adverse reactions are myelosuppression, gastrointestinal reactions, are reversible. Conclusions The combination therapy of Zijin and Zefei respectively with cisplatin in the treatment of recurrent or distant metastasis, especially anthracycline-resistant advanced breast cancer, has similar efficacy and side effects.